PXS.AX - Pharmaxis Ltd

ASX - ASX Delayed Price. Currency in AUD

Pharmaxis Ltd

20 Rodborough Road
Frenchs Forest, NSW 2086
61 2 9454 7200

IndustryDrug Manufacturers - Major
Full Time Employees67

Key Executives

NameTitlePayExercisedYear Born
Mr. Gary Jonathan Phillips BPharm, MBACEO & DirectorN/AN/A1961
Mr. David Morris McGarvey BA, CA, CPACFO & Company Sec.N/AN/A1956
Mr. Wolfgang G. Jarolimek B.Sc. Ph.D.Head of Drug DiscoveryN/AN/A1964
Dr. Brett Charlton MBBS Ph.D.Medical DirectorN/AN/A1956
Ms. Kristen Morgan BSc,PGDipBusAdmin,MMedScExec. Officer198.67kN/A1972
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Pharmaxis Ltd engages in the research, development, and commercialization of human healthcare products for the treatment and management of chronic diseases worldwide. The company operates through two segments, Bronchitol and Aridol Business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, a lung function test used to diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness. The company's drug discovery programs include amine oxidase drug platform programs, such as semicarbazide-sensitive amine oxidase (SSAO) inhibitor BI 1467335 for the treatment of inflammation; selective LOXL2 inhibitor for NASH, liver, IPF, and kidney fibrosis; LOX inhibitor for scaring and cancer; and other SSAO inhibitor programs. It is also developing ASM8 an inhaled drug candidate in development for the treatment of severe asthma; and Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd has a collaboration agreement with Synairgen plc for the Phase I clinical trial of the LOXL2 inhibitor PXS-5382. The company was founded in 1998 and is headquartered in Frenchs Forest, Australia.

Corporate Governance

Pharmaxis Ltd’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.